Last updated: 2026-09-05 22:20:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Genprex, Inc. (GNPX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.50, with a market capitalization of $2.88M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.37 to $1,210.00. This page covers its latest market performance, valuation, price trends and company information.
$2.88M | |
$3.60 | |
$855,795.60 | |
$3.37 | |
$3.43 | |
35.18K | |
-- | |
-- | |
$1,210.00 | |
$3.37 | |
-- | |
-- |
Genprex, Inc. (GNPX) last closed at $3.43 as of 2026-09-04 23:43:00, unchanged from the previous close of $3.43.
During the latest regular trading session, GNPX traded between $3.37 and $855,795.60, with a volume of 35.18K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Genprex, Inc. (GNPX) moved from $3.73 to $3.50, representing a decline of 6.17% ($0.23).
The stock traded between $3.39 and $3.61 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 65.94 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.0%
GNPX is currently trading at $3.50, placing it 0.0% of the way from its 52-week low of $3.37 to its 52-week high of $1,210.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 13 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Genprex, Inc. (GNPX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.